ULTRAVIOLET A-1 LIGHT THERAPY IN HUMANS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

系统性红斑狼疮患者的紫外线 A-1 光疗法

• 批准号: 5224907
• 负责人: Hugh McGrath
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5224907
• 关键词: clinical research; human subject; human therapy evaluation; systemic lupus erythematosus; temperature; ultraviolet therapy

UVA (320-340nm) light is an effective yet innocuous therapeutic modality for the treatment of patients with systemic lupus erythematosus (SLE). The long term objectives are to learn whether UV-A1 light can control disease long term, whether it becomes toxic with prolonged use, and how its delivery can be optimized for both short and long term trials. The specific aims will be to evaluate over the short and long term dose level, required frequency of treatments, the effect of ambient temperature during treatment, the most advantageous lamp placement, the interaction of UV-A light with other therapies and the mechanisms of UVA's action. The observations will serve to develop this therapy, the first of its kind.

UVA（320- 340 nm）光是一种有效但无害的治疗方式 用于治疗系统性红斑狼疮（SLE）患者。 长期目标是了解UV-A1光是否可以控制 长期使用是否会中毒，以及如何 其递送可针对短期和长期试验进行优化。 的 具体目标是评估短期和长期剂量 水平、所需治疗频率、环境影响 治疗过程中的温度，最有利的灯的位置， UV-A光与其他疗法的相互作用及其机制 UVA的行动。 观察结果将有助于发展这种疗法， 第一个这样的。